GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » EV-to-Revenue

Vidac Pharma Holding (STU:T9G) EV-to-Revenue : (As of Jul. 17, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vidac Pharma Holding's enterprise value is €27.84 Mil. Vidac Pharma Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil. Therefore, Vidac Pharma Holding's EV-to-Revenue for today is .

The historical rank and industry rank for Vidac Pharma Holding's EV-to-Revenue or its related term are showing as below:

STU:T9G's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.25
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-17), Vidac Pharma Holding's stock price is €0.508. Vidac Pharma Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00. Therefore, Vidac Pharma Holding's PS Ratio for today is .

Vidac Pharma Holding EV-to-Revenue Historical Data

The historical data trend for Vidac Pharma Holding's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding EV-to-Revenue Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
EV-to-Revenue
- - -

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Vidac Pharma Holding's EV-to-Revenue

For the Biotechnology subindustry, Vidac Pharma Holding's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's EV-to-Revenue falls into.


;
;

Vidac Pharma Holding EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vidac Pharma Holding's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=27.843/0
=

Vidac Pharma Holding's current Enterprise Value is €27.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vidac Pharma Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding  (STU:T9G) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vidac Pharma Holding's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.508/0
=

Vidac Pharma Holding's share price for today is €0.508.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » EV-to-Revenue
Comparable Companies
FRA:T5O0 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX INSM HKSE:01801 SMMT RPRX XKRX:196170 INCY HKSE:02269 OCSE:GMAB HKSE:01177
Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Website
https://www.vidacpharma.com
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines